Modern strategies in therapy of elderly patients with multiple myeloma

We used the bortezomib plus dexamethasone (VD) and bortezomib plus MP (VMP) in 56 previously untreated elderly patients with multiple myeloma. The patients were 65–89 years old. For patients who received bortezomib plus MP the overall response rate was 83%. 33.3% of patients achieved complete respon...

Full description

Saved in:

Bibliographic Details
Main Authors:	S. S. Bessmeltsev, L. V. Stelmashenko, E. V. Kariagina, N. V. Stepanova, G. N. Salogub, T. L. Shelkovskaya, T. A. Malakhova, I. A. Skorokhod, E. I. Podoltseva, N. O. Saraeva, O. I. Kovalev, A. V. Klimovich, N. V. Medvedeva, K. M. Abdulkadyrov, L. I. Krylova, T. H. Potrachkova, M. A. Novikova, E. R. Machulaitene, E. I. Darskaya, L. M. Matukhina, N. A. Kotova, O. Ya. Kostina, I. A. Novokreshchenova
Format:	Article
Language:	Russian
Published:	ABV-press 2022-11-01
Series:	Онкогематология
Subjects:	bortezomib multiple myeloma treatment complete remission overall survival neuropathy
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/757
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Modern strategies in therapy of elderly patients with multiple myeloma

Similar Items